Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia
Abstract
BACKGROUND:
Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce.
METHODS:
To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation.
RESULTS:
We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis.
CONCLUSIONS:
This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
Formats available
You can view the full content in the following formats:
Supplemental Material
File (hyp_hype-2024-23362_supp1.xlsx)
- Download
- 2.26 MB
File (hyp_hype-2024-23362_supp10.xlsx)
- Download
- 35.12 KB
File (hyp_hype-2024-23362_supp11.xlsx)
- Download
- 142.45 KB
File (hyp_hype-2024-23362_supp12.xlsx)
- Download
- 152.80 KB
File (hyp_hype-2024-23362_supp13.xlsx)
- Download
- 72.16 KB
File (hyp_hype-2024-23362_supp14.pdf)
- Download
- 5.50 MB
File (hyp_hype-2024-23362_supp3.xlsx)
- Download
- 39.59 KB
File (hyp_hype-2024-23362_supp4.xlsx)
- Download
- 16.49 MB
File (hyp_hype-2024-23362_supp5.xlsx)
- Download
- 8.78 MB
File (hyp_hype-2024-23362_supp6.xlsx)
- Download
- 20.13 KB
File (hyp_hype-2024-23362_supp7.xlsx)
- Download
- 24.28 KB
File (hyp_hype-2024-23362_supp8.xlsx)
- Download
- 2.58 MB
File (hyp_hype-2024-23362_supp9.xlsx)
- Download
- 344.08 KB
Information & Authors
Information
Published In
Copyright
© 2024 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
History
Received: 22 May 2024
Accepted: 7 October 2024
Published online: 23 October 2024
Keywords
Subjects
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
Purchase this article to access the full text.
eLetters(0)
eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.
Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.